Anchorage-independent growth of Ewing sarcoma cells under serum-free conditions is not associated with stem-cell like phenotype and function

Leuchte,Katharina; Altvater,Bianca; Hoffschlag,Simeon; Potratz,Jenny; Meltzer,Jutta; Clemens,Dagmar; Luecke,Andrea; Hardes,Jendrik; Dirksen,Uta; Juergens,Heribert; Kailayangiri,Sareetha; Rossig,Claudia

doi:10.3892/or.2014.3269

Anchorage-independent growth of Ewing sarcoma cells under serum-free conditions is not associated with stem-cell like phenotype and function

Authors:
- Katharina Leuchte
- Bianca Altvater
- Simeon Hoffschlag
- Jenny Potratz
- Jutta Meltzer
- Dagmar Clemens
- Andrea Luecke
- Jendrik Hardes
- Uta Dirksen
- Heribert Juergens
- Sareetha Kailayangiri
- Claudia Rossig
View Affiliations

Affiliations: Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, D-48149 Muenster, Germany, Department of Orthopedic Surgery, University Hospital Muenster, D-48149 Muenster, Germany
Published online on: June 13, 2014 https://doi.org/10.3892/or.2014.3269
Pages: 845-852

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Novel treatment strategies for Ewing sarcoma aim to eliminate residual tumor cells that have maintained the capacity to reinitiate tumor growth after intensive conventional therapy. Preclinical models that more closely mimic in vivo tumor growth than standard monolayer cultures are needed. Sphere formation under anchorage-independent, serum-free conditions has been proposed to enrich for cells with tumor-initiating, stem cell-like properties in various solid cancers. In the present study, we assessed the phenotype and functional stem cell characteristics of Ewing sarcoma spheres. Spheres were generated under serum-free culture conditions from four Ewing sarcoma cell lines and four relapse tumor biopsies. Standard monolayer cultures were established as controls. Median levels of surface expression of the Ewing sarcoma marker CD99 as well as the supposed stem cell marker CD133 and the neural crest marker CD57 were comparable between spheres and monolayers. Ewing sarcoma spheres from individual tumors failed to continuously self-renew by secondary sphere formation. They contained variable proportions of side populations (SPs). Sphere culture did not enhance the in vivo tumorigenicity of Ewing sarcoma cells in a murine xenograft model. We conclude that sphere formation under serum-free conditions is not a reliable tool to enrich for cells with stem cell characteristics in Ewing sarcoma. By mimicking the anchorage-independent, multicellular growth of Ewing sarcoma micrometastases, in vitro sphere growth may still add value as a preclinical tool to evaluate the efficacy of novel therapeutics.

View Figures

View References

1	Paulussen M, Craft AW, Lewis I, et al: Results of the EICESS-92 study: two randomized trials of Ewing’s sarcoma treatment - cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 26:4385–4393. 2008.PubMed/NCBI
2	Paulussen M, Ahrens S, Burdach S, et al: Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol. 9:275–281. 1998. View Article : Google Scholar
3	Stahl M, Ranft A, Paulussen M, et al: Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer. 57:549–553. 2011. View Article : Google Scholar : PubMed/NCBI
4	Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H and Campana D: Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res. 16:3901–3909. 2010. View Article : Google Scholar : PubMed/NCBI
5	Mackall CL, Rhee EH, Read EJ, et al: A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res. 14:4850–4858. 2008. View Article : Google Scholar : PubMed/NCBI
6	Thiel U, Pirson S, Müller-Spahn C, et al: Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells. Br J Cancer. 104:948–956. 2011. View Article : Google Scholar : PubMed/NCBI
7	Erkizan HV, Kong Y, Merchant M, et al: A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing’s sarcoma. Nat Med. 15:750–756. 2009.PubMed/NCBI
8	Braun S, Pantel K, Müller P, et al: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 342:525–533. 2000. View Article : Google Scholar : PubMed/NCBI
9	Woelfle U, Breit E, Zafrakas K, et al: Bi-specific immunomagnetic enrichment of micrometastatic tumour cell clusters from bone marrow of cancer patients. J Immunol Methods. 300:136–145. 2005. View Article : Google Scholar : PubMed/NCBI
10	Freedman VH and Shin SI: Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell. 3:355–359. 1974. View Article : Google Scholar : PubMed/NCBI
11	Shin SI, Freedman VH, Risser R and Pollack R: Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci USA. 72:4435–4439. 1975. View Article : Google Scholar : PubMed/NCBI
12	Lee J, Kotliarova S, Kotliarov Y, et al: Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 9:391–403. 2006. View Article : Google Scholar : PubMed/NCBI
13	Lawlor ER, Scheel C, Irving J and Sorensen PH: Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors. Oncogene. 21:307–318. 2002. View Article : Google Scholar : PubMed/NCBI
14	Wahl J, Bogatyreva L, Boukamp P, et al: Ewing’s sarcoma cells with CD57-associated increase of tumorigenicity and with neural crest-like differentiation capacity. Int J Cancer. 127:1295–1307. 2010.
15	Ottaviano L, Schaefer KL, Gajewski M, et al: Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer. 49:40–51. 2010. View Article : Google Scholar : PubMed/NCBI
16	Landuzzi L, De Giovanni C, Nicoletti G, et al: The metastatic ability of Ewing’s sarcoma cells is modulated by stem cell factor and by its receptor c-kit. Am J Pathol. 157:2123–2131. 2000.
17	Suvà ML, Riggi N, Stehle JC, et al: Identification of cancer stem cells in Ewing’s sarcoma. Cancer Res. 69:1776–1781. 2009.
18	Al Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003.
19	Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature. 432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
20	Goodell MA, Rosenzweig M, Kim H, et al: Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med. 3:1337–1345. 1997. View Article : Google Scholar
21	Coulon A, Flahaut M, Mühlethaler-Mottet A, et al: Functional sphere profiling reveals the complexity of neuroblastoma tumor-initiating cell model. Neoplasia. 13:991–1004. 2011.PubMed/NCBI
22	Hansford L, Smith K, Datti A, et al: Tumor initiating cells from neuroblastoma, a neural crest-derived tumor. Int J Dev Neurosci. 24:4892006. View Article : Google Scholar
23	Mahller YY, Williams JP, Baird WH, et al: Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One. 4:e42352009. View Article : Google Scholar : PubMed/NCBI
24	Rainusso N, Brawley VS, Ghazi A, et al: Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther. 19:212–217. 2012. View Article : Google Scholar : PubMed/NCBI
25	Walter D, Satheesha S, Albrecht P, et al: CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS One. 6:e195062011. View Article : Google Scholar : PubMed/NCBI
26	Zhang S, Balch C, Chan MW, et al: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68:4311–4320. 2008. View Article : Google Scholar : PubMed/NCBI
27	Brown CE, Starr R, Martinez C, et al: Recognition and killing of brain tumor stem-like initiating cells by CD8⁺ cytolytic T cells. Cancer Res. 69:8886–8893. 2009. View Article : Google Scholar : PubMed/NCBI
28	Gibbs CP, Kukekov VG, Reith JD, et al: Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia. 7:967–976. 2005. View Article : Google Scholar : PubMed/NCBI
29	Zhong Y, Guan K, Guo S, et al: Spheres derived from the human SK-RC-42 renal cell carcinoma cell line are enriched in cancer stem cells. Cancer Lett. 299:150–160. 2010. View Article : Google Scholar : PubMed/NCBI
30	Charafe-Jauffret E, Ginestier C, Iovino F, et al: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 69:1302–1313. 2009. View Article : Google Scholar : PubMed/NCBI
31	O’Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 445:106–110. 2007.PubMed/NCBI
32	Yin S, Li J, Hu C, et al: CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 120:1444–1450. 2007. View Article : Google Scholar : PubMed/NCBI
33	Jiang X, Gwye Y, Russell D, et al: CD133 expression in chemo-resistant Ewing sarcoma cells. BMC Cancer. 10:1162010. View Article : Google Scholar : PubMed/NCBI
34	Hirschmann-Jax C, Foster AE, Wulf GG, et al: A distinct ‘side population’ of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. 101:14228–14233. 2004.
35	Murase M, Kano M, Tsukahara T, et al: Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas. Br J Cancer. 101:1425–1432. 2009. View Article : Google Scholar : PubMed/NCBI
36	Broadley KW, Hunn MK, Farrand KJ, et al: Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme. Stem Cells. 29:452–461. 2011. View Article : Google Scholar : PubMed/NCBI
37	Barrett LE, Granot Z, Coker C, et al: Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. Cancer Cell. 21:11–24. 2012. View Article : Google Scholar : PubMed/NCBI
38	Feder-Mengus C, Ghosh S, Weber WP, et al: Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes. Br J Cancer. 96:1072–1082. 2007. View Article : Google Scholar
39	Fischer K, Hoffmann P, Voelkl S, et al: Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 109:3812–3819. 2007. View Article : Google Scholar : PubMed/NCBI
40	Hirschhaeuser F, Leidig T, Rodday B, Lindemann C and Mueller-Klieser W: Test system for trifunctional antibodies in 3D MCTS culture. J Biomol Screen. 14:980–990. 2009. View Article : Google Scholar : PubMed/NCBI
41	Jääskeläinen J, Kalliomäki P, Paetau A and Timonen T: Effect of LAK cells against three-dimensional tumor tissue. In vitro study using multi-cellular human glioma spheroids as targets. J Immunol. 142:1036–1045. 1989.PubMed/NCBI
42	Lakshmikanth T, Burke S, Ali TH, et al: NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest. 119:1251–1263. 2009. View Article : Google Scholar : PubMed/NCBI
43	Parkhurst MR, Riley JP, Dudley ME and Rosenberg SA: Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res. 17:6287–6297. 2011. View Article : Google Scholar : PubMed/NCBI
44	Geller MA, Cooley S, Judson PL, et al: A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 13:98–107. 2011. View Article : Google Scholar : PubMed/NCBI